Using stem cell eye drops — ones containing mesenchymal stem cells, or MSCs, which can give rise to other cell types — was shown to ease the signs and symptoms of refractory, or hard-to-treat, dry eye disease in adults with and without Sjögren’s disease, according to new data from…
News
Cullinan Therapeutics is planning the launch of a clinical trial in the U.S. to test its treatment candidate CLN-978 in people with Sjögren’s disease. The study will be open to Sjögren’s patients whose disease is active and moderate to severe, and who are positive for anti-SSA/Ro antibodies and/or…
Immunovant is planning to launch a potentially registrational clinical trial this summer to test its treatment candidate IMVT-1402 in people with Sjögren’s disease. The company said that its investigational new drug application — a formal request to the U.S. Food and Drug Administration (FDA) seeking permission to start…
Men with Sjögren’s disease show more early signs of lung and heart dysfunction than women and may be at an increased risk of developing pulmonary hypertension, a cardiovascular complication of Sjögren’s, a study reports. “As male patients demonstrated a greater predisposition to developing [pulmonary hypertension] … regular echocardiographic…
A naturally occurring molecule that has the ability to regulate gene activity may represent a promising therapeutic target for Sjögren’s disease and other autoimmune conditions, according to a study. Mimicking the activity of the molecule, miR-216a-3p, eased inflammation and scarring in a rat model of the disease. Its therapeutic…
More severe salivary gland damage and lymph node enlargement detected by ultrasound examination are associated with higher disease activity in primary Sjögren’s disease, a study in South Korea reports. Also, researchers found that more severe salivary gland damage was tied to a higher prevalence of laboratory risk factors for…
April is Sjögren’s Awareness Month, and a U.S.-based nonprofit is gearing up to help the community spread the word about Sjögren’s disease — and the many ways people impacted by this autoimmune condition can get involved. For this year’s awareness month, the Sjögren’s Foundation is inviting supporters…
Nipocalimab, an experimental antibody-based therapy being developed by Johnson & Johnson, was granted fast track status by the U.S. Food and Drug Administration (FDA) for adults with moderate to severe Sjögren’s disease. Fast track status is given to candidate therapies for serious health conditions with the…
Nearly 80% of women with Sjögren’s disease experience sexual dysfunction, with common symptoms including vaginal dryness, lower sexual satisfaction, and difficulty with arousal, a Chinese study finds. The findings highlight the need of “increased awareness and recognition of sexual health in clinical practice,” the researchers wrote, adding that “policymakers…
People with primary Sjögren’s disease diagnosed at a younger age and who harbor certain self-reactive antibodies are more likely to have kidney involvement, a study in South Korea suggests. While most with kidney involvement were asymptomatic, about a third had impaired kidney function when they were diagnosed and 25%…
Recent Posts
- Childhood-onset Sjögren’s can cause lasting damage to organs: Study
- Salivary duct treatment eases dry mouth in Sjögren’s disease: Study
- 4 genes linked to inflammatory cell death very active in Sjögren’s
- AI can see what doctors miss to accurately diagnose Sjögren’s
- Worse fatigue tied to more pain in people with Sjögren’s, study finds
- Dazodalibep therapy now in Phase 3 testing for Sjögren’s disease
- Sjögren’s treatment ianalumab shows rapid disease relief in trials
- Sjögren’s patients on nipocalimab report less pain, dryness in trial
- Ouro starts Phase 1b trial of OM336 for Sjögren’s disease treatment
- Telitacicept eases Sjögren’s disease activity in Phase 3 trial